| Global Markets Directs, 'Uterine
Cancer - Pipeline Review, H2 2013', provides an overview of the indications
therapeutic pipeline. This report provides information on the therapeutic
development for Uterine Cancer, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Uterine Cancer. Uterine Cancer -
Pipeline Review, Half Year is built using data and information sourced from
Global Markets Directs proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by Global Markets
Directs team. Note: Certain sections in the report
may be removed or altered based on the availability and relevance of data for
the indicated disease.
Scope * A snapshot of the global
therapeutic scenario for Uterine Cancer. * A review of the Uterine Cancer
products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources. * Coverage of products based on
various stages of development ranging from discovery till registration stages. * A feature on pipeline projects on
the basis of monotherapy and combined therapeutics. * Coverage of the Uterine Cancer
pipeline on the basis of route of administration and molecule type. * Key discontinued pipeline
projects. * Latest news and deals relating to
the products.
Reasons to buy * Identify and understand important
and diverse types of therapeutics under development for Uterine Cancer. * Identify emerging players with
potentially strong product portfolio and design effective counter-strategies to
gain competitive advantage. * Plan mergers and acquisitions
effectively by identifying players of the most promising pipeline. * Devise corrective measures for pipeline
projects by understanding Uterine Cancer pipeline depth and focus of Indication
therapeutics. * Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope. * Modify the therapeutic portfolio
by identifying discontinued projects and understanding the factors that drove
them from pipeline.
To order this report: Email: support@researchonglobalmarkets.com US:
+1 866 325 7446 UK: +44 203 514 2363 India: +91 22 4098 7600 SOURCE: Researchonglobalmarkets.com
RELATED LINK: Uterine Cancer - Pipeline Review, H2 2013
RELATED VIDEO:
| 
